What shareholders can do to beat the market with MannKind Corporation (MNKD) stock

In the latest session, MannKind Corporation (NASDAQ: MNKD) closed at 3.48 down -2.52% from its previous closing price of $3.57. In other words, the price has decreased by $-0.0900 from its previous closing price. On the day, 5244575 shares were traded. MNKD reached its highest trading level at $3.5450 during the session, while it also had its lowest trading level at $3.3700.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



For a deeper understanding of MannKind Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.90 and its Current Ratio is at 3.20.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on May 14, 2021, initiated with a Sector Perform rating and assigned the stock a target price of $5.

On December 24, 2019, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $2.50.

On October 25, 2019, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on October 25, 2019, with a $3 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 29 when Thomson David sold 7,000 shares for $3.67 per share. The transaction valued at 25,690 led to the insider holds 726,035 shares of the business.

Galindo Alejandro sold 4,615 shares of MNKD for $17,771 on Aug 22. The EVP Endocrine Business Unit now owns 777,075 shares after completing the transaction at $3.85 per share. On Jul 31, another insider, Galindo Alejandro, who serves as the EVP Endocrine Business Unit of the company, bought 5,000 shares for $2.93 each. As a result, the insider paid 14,650 and bolstered with 781,690 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 14.30.

Stock Price History:

Over the past 52 weeks, MNKD has reached a high of $5.44, while it has fallen to a 52-week low of $2.49. The 50-Day Moving Average of the stock is 3.8488, while the 200-Day Moving Average is calculated to be 3.7899.

Shares Statistics:

For the past three months, MNKD has traded an average of 4.67M shares per day and 6.2M over the past ten days. A total of 253.64M shares are outstanding, with a floating share count of 241.06M. Insiders hold about 2.30% of the company’s shares, while institutions hold 47.60% stake in the company. Shares short for MNKD as of Jul 14, 2022 were 28.84M with a Short Ratio of 6.71, compared to 28.05M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 11.42% and a Short% of Float of 11.68%.

Earnings Estimates

There are 5 different market analysts currently analyzing its stock. On average, analysts expect EPS of $-0.09 for the current quarter, with a high estimate of $-0.08 and a low estimate of $-0.11, while EPS last year was $-0.14. The consensus estimate for the next quarter is $-0.08, with high estimates of $-0.05 and low estimates of $-0.11.

Analysts are recommending an EPS of between $-0.11 and $-0.41 for the fiscal current year, implying an average EPS of $-0.29. EPS for the following year is $-0.1, with 5 analysts recommending between $0.02 and $-0.24.

Revenue Estimates

A total of 6 analysts have provided revenue estimates for MNKD’s current fiscal year. The highest revenue estimate was $101.3M, while the lowest revenue estimate was $69.65M, resulting in an average revenue estimate of $81.76M. In the same quarter a year ago, actual revenue was $75.44M, up 8.40% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $150.2M in the next fiscal year. The high estimate is $192.6M and the low estimate is $126.4M. The average revenue growth estimate for next year is up 83.70% from the average revenue estimate for this year.